Publikasi Scopus FKUI 2021 per tanggal 31 Agustus 2021 (582 artikel)

Ross J., Jiamsakul A., Kumarasamy N., Azwa I., Merati T.P., Do C.D., Lee M.P., Ly P.S., Yunihastuti E., Nguyen K.V., Ditangco R., Ng O.T., Choi J.Y., Oka S., Sohn A.H., Law M.
57193109926;55285745500;7003549856;55553159100;57203678680;56658396600;56143671100;9743902800;8850357600;56370854300;55406840800;57203665233;57214878200;57216171596;7006405275;57222965808;
Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific
2021
HIV Medicine
22
3
201
211
TREAT Asia/amfAR –The Foundation for AIDS Research, Bangkok, Thailand; The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia; Bach Mai Hospital, Hanoi, Viet Nam; Queen Elizabeth Hospital, Hong Kong; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Tan Tock Seng Hospital, Singapore, Singapore; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; National Center for Global Health and Medicine, Tokyo, Japan
Ross, J., TREAT Asia/amfAR –The Foundation for AIDS Research, Bangkok, Thailand; Jiamsakul, A., The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; Azwa, I., Infectious Diseases Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Merati, T.P., Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia; Do, C.D., Bach Mai Hospital, Hanoi, Viet Nam; Lee, M.P., Queen Elizabeth Hospital, Hong Kong; Ly, P.S., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Yunihastuti, E., Faculty of Medicine, Universitas Indonesia - Dr Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Nguyen, K.V., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Ditangco, R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Ng, O.T., Tan Tock Seng Hospital, Singapore, Singapore; Choi, J.Y., Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Oka, S., National Center for Global Health and Medicine, Tokyo, Japan; Sohn, A.H., TREAT Asia/amfAR –The Foundation for AIDS Research, Bangkok, Thailand; Law, M., The Kirby Institute, UNSW Sydney, Kensington, NSW, Australia
Objectives: To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. Methods: Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and genotypic resistance testing were collected or testing was conducted between July 2015 and May 2017 at 12 Asia-Pacific sites. Virological failure (VF) was defined as VL > 1000 copies/mL with a second VL > 1000 copies/mL within 3–6 months. FASTA files were submitted to Stanford University HIV Drug Resistance Database and RAMs were compared against the IAS-USA 2019 mutations list. VF risk factors were analysed using logistic regression. Results: Of 1378 patients, 74% were male and 70% acquired HIV through heterosexual exposure. At second-line switch, median [interquartile range (IQR)] age was 37 (32–42) years and median (IQR) CD4 count was 103 (43.5–229.5) cells/µL; 93% received regimens with boosted protease inhibitors (PIs). Median duration on second line was 3 years. Among 101 patients (7%) with VF, CD4 count > 200 cells/µL at switch [odds ratio (OR) = 0.36, 95% confidence interval (CI): 0.17–0.77 vs. CD4 ≤ 50) and HIV exposure through male–male sex (OR = 0.32, 95% CI: 0.17–0.64 vs. heterosexual) or injecting drug use (OR = 0.24, 95% CI: 0.12–0.49) were associated with reduced VF. Of 41 (41%) patients with resistance data, 80% had at least one RAM to nonnucleoside reverse transcriptase inhibitors (NNRTIs), 63% to NRTIs, and 35% to PIs. Of those with PI RAMs, 71% had two or more. Conclusions: There were low proportions with VF and significant RAMs in our cohort, reflecting the durability of current second-line regimens. © 2020 British HIV Association
Asia; drug resistance; HIV; second-line antiretroviral therapy; virological failure
anti human immunodeficiency virus agent; emtricitabine; Human immunodeficiency virus proteinase inhibitor; integrase inhibitor; lamivudine; lopinavir; nonnucleoside reverse transcriptase inhibitor; raltegravir; RNA directed DNA polymerase inhibitor; tenofovir; adult; antiretroviral therapy; antiviral resistance; Article; Cambodia; CD4 lymphocyte count; cohort analysis; comparative study; cross-sectional study; data base; female; gene mutation; genotyping technique; heterosexuality; Hong Kong; human; Human immunodeficiency virus; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; India; Indonesia; injection drug user; Japan; major clinical study; Malaysia; male; men who have sex with men; middle aged; Philippines; priority journal; prospective study; retr
Blackwell Publishing Ltd
14642662
33151020
Article
Q1
1530
2201